AMR life science industry 2020 report: Successes and setbacks in fighting superbugs
AMR Industry Alliance report released today provides a unique snapshot
of the life science industry’s collective efforts in delivering on their commitments to tackle the rise of antimicrobial resistance (AMR). Results from the Alliance’s survey of biotech, diagnostics, generic and large research-based biopharmaceutical companies are mixed. Positive results include sustained investment in early R&D and diagnostics for AMR-related products (including antibiotics, antifungals, vaccines) and major strides in responsible manufacturing of antibiotics. Worryingly, low levels of
investment for later and more costly stages of R&D for AMR-related products may mean that many promising early-stage compunds will never reach patients unless governments put in place new mechanisms and incentives for antibiotic development.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.